Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Operating Expenses (2016 - 2026)

Akebia Therapeutics has reported Operating Expenses over the past 10 years, most recently at $53.6 million for Q4 2025.

  • Quarterly Operating Expenses rose 32.64% to $53.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $173.2 million through Dec 2025, up 17.47% year-over-year, with the annual reading at $173.2 million for FY2025, 17.47% up from the prior year.
  • Operating Expenses was $53.6 million for Q4 2025 at Akebia Therapeutics, up from $44.9 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $88.8 million in Q1 2022 and troughed at $35.3 million in Q2 2024.
  • The 5-year median for Operating Expenses is $46.8 million (2023), against an average of $55.0 million.
  • Year-over-year, Operating Expenses plummeted 48.89% in 2023 and then skyrocketed 32.64% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $75.4 million in 2021, then dropped by 15.0% to $64.1 million in 2022, then crashed by 43.58% to $36.2 million in 2023, then grew by 11.84% to $40.4 million in 2024, then skyrocketed by 32.64% to $53.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Operating Expenses are $53.6 million (Q4 2025), $44.9 million (Q3 2025), and $38.5 million (Q2 2025).